durvalumab,paclitaxel,carboplatin,cisplatin,gemcitabine,pemetrexed
astrazeneca
['ts,perio,i', 'durva', 'nsclc', 'aegean', 'sclc']
results from the aegean trial suggest that adding perioperative durvalumab to neoadjuvant chemotherapy can improve outcomes in patients with resectable nsclc. presented at aacr 2023. #aacr23 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.